XTL Biopharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference
08 January 2008 - 1:35AM
PR Newswire (US)
VALLEY COTTAGE, N.Y., Jan. 7 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today
that Ron Bentsur, the Company's Chief Executive Officer, is
scheduled to present at the 26th Annual JPMorgan Healthcare
Conference. Mr. Bentsur will present an overview of the Company
including a discussion of Bicifadine, the Company's late-stage
clinical compound for the treatment of diabetic neuropathic pain.
Mr. Bentsur's presentation will take place on Thursday, January 10,
2008 at 1:00 pm PST at the Westin St. Francis in San Francisco. A
live webcast of the presentation will be available at:
http://www.metameetings.com/webcasts/jpmorgan/healthcare08. An
archived version of the webcast will be available following the
conclusion of the live presentation. ABOUT XTL BIOPHARMACEUTICALS
LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the
development of therapeutics for the treatment of neuropathic pain
and HCV. XTL is developing Bicifadine, a serotonin and
norepinephrine reuptake inhibitor, for the treatment of diabetic
neuropathic pain, which is currently in a Phase 2b study. XTL is
also developing novel pre-clinical HCV small molecule inhibitors.
XTL also has an active in-licensing and acquisition program
designed to identify and acquire additional drug candidates. XTL is
publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd.
CONTACT: Ron Bentsur, Chief Executive Officer, XTL
Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225 Web site:
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024